ReachMD CME

CME credits: 1.00 Valid until: 11-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/Hepatic-Encephalopathy-More-Common-Than-You-Think/39786/ This series of brief episodes focuses on the early recognition and clinical management of hepatic encephalopathy (HE). Drs. Arun Jesudian and Nancy Reau examine subtle signs that may indicate minimal or covert HE and offer strategies for timely diagnosis. The discussion covers practical tools for detection, the role of nutrition and pharmacologic therapy, and evidence-based approaches to prevent progression and hospitalization. Emerging therapies and ongoing clinical trials are also discussed to highlight future directions in HE treatment.

CME credits: 0.25 Valid until: 26-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-clear-horizon-in-plaque-psoriasis-an-update-on-investigational-oral-therapies/37867/ Among patients with moderate to severe plaque psoriasis, oral formulations of therapies is often a preferred route of administration, particularly among those with a fear of needles, which can negatively impact patent compliance. However, the currently available oral small-molecule therapies apremilast and deucravacitinib have demonstrated lower levels of skin clearance relative to biologics for the treatment of plaque psoriasis. Investigation into novel oral small-molecule therapies is ongoing, such as next-generation TYK2 inhibitors and the first-in-class investigational targeted oral peptide icotrokinra, which selectively targets IL-23 receptor signaling. These therapies have demonstrated dramatically improved clinical responses versus comparators and may significantly impact the current treatment paradigm for plaque psoriasis. =

CME credits: 0.50 Valid until: 07-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/updates-in-major-depressive-disorder-with-insomnia/36556/ Approximately 75% to 90% of patients with depression experience insomnia. This means that a very significant portion of individuals struggling with depression also have difficulty sleeping. Join Drs. Michael Thase and Andrew Krystal for this expert discussion to learn about the most recent data presented at the Psych Congress 2025 in San Diego on emerging therapies, such as the selective OX2R antagonists to treat major depressive disorder with insomnia. =

CME credits: 0.50 Valid until: 29-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/mechanism-driven-gmg-therapy-fcrn-antagonists-and-the-rise-of-precision-neurology/36277/ This Clinical Countdown addresses key challenges in diagnosing and managing generalized myasthenia gravis (gMG), with a focus on FcRn antagonists. Drs. Edmundson and Goyal review diagnostic challenges in gMG, along with the mechanism of FcRn blockade and how it compares to traditional therapies such as corticosteroids, IVIG, and plasma exchange. The discussion highlights pivotal phase 3 trials (ADAPT, MycarinG, and VIVACITY MG), evaluating differences in efficacy, dosing schedules, and administration routes for agents like efgartigimod, rozanolixizumab, and nipocalimab. Faculty discuss how data from these trials informs individualized treatment planning and facilitates shared decision-making. =

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-tipping-the-balance/39660/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/you-cant-diagnose-mhe-unless-you-diagnose-cirrhosis/39661/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/diagnosing-minimal-hepatic-encephalopathy-theres-an-app-for-that/39662/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-whats-sarcopenia-got-to-do-with-it/39663/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/treatment-of-overt-hepatic-encephalopathy/39664/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-unmet-therapeutic-needs/39665/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-an-ominous-sign/39666/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/hepatic-encephalopathy-an-ominous-sign/39278/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 23-10-2026 Claim your CME credit at https://reachmd.com/cme/gastroenterology-and-hepatology/the-clinical-spectrum-of-hepatic-encephalopathy/39304/ This series of brief episodes addresses how primary care providers can recognize early and often subtle signs of hepatic encephalopathy to support timely diagnosis and intervention. Drs. Robert Brown and Steven Flamm discuss clinical indicators that may prompt treatment initiation or specialist referral. The discussion focuses on optimizing patient care through early recognition and appropriate management strategies in the primary care setting.

CME credits: 1.00 Valid until: 22-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/primary-biliary-cholangitis-shining-light-on-an-invisible-female-health-burden/36709/ This WHAV 2025 session examines primary biliary cholangitis (PBC), a chronic autoimmune liver disease that predominantly affects women and often goes unrecognized. Tailored for clinicians who play a key role in identifying symptoms and initiating referrals, the session outlines diagnostic criteria—including AMA positivity and elevated ALP—and clarifies when specialist evaluation is warranted. Treatment strategies cover UDCA and newer agents like elafibranor and seladelpar for nonresponders. The discussion also addresses symptom burden, extrahepatic manifestations, and reproductive-stage considerations, including pregnancy. =

CME credits: 1.00 Valid until: 22-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/endovoice-live-endometriosisa-chronic-burden-of-reproductive-years/37176/ This dynamic symposium will guide clinicians through a modern, patient-centered approach to endometriosis care. Faculty will explore how early diagnosis can improve physical and psychosocial outcomes, examine tools to advance equity and shared decision-making, and evaluate the latest evidence for GnRH antagonists as a nonsurgical treatment strategy. The session concludes with a patient perspective that illustrates how lived experience can inform more patient-centered, multidisciplinary care that incorporates medical treatment and shared decision-making. =

CME credits: 0.50 Valid until: 21-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-in-patients-with-ohcm-the-emerging-role-of-cardiac-myosin-inhibitors/33176/ Hypertrophic cardiomyopathy (HCM) management is being transformed by advances in diagnostics and the emergence of targeted therapies. In this program, leading international experts review challenges in early recognition, the evolving role of beta-blockers and traditional therapies, and the clinical impact of novel cardiac myosin inhibitors. Data from pivotal studies—including the landmark MAPLE-HCM trial—are examined in depth, with a focus on exercise capacity, gradient reduction, biomarkers, and patient outcomes. Faculty also share practical strategies for patient selection, monitoring, and translating trial evidence into daily cardiology practice. =

CME credits: 1.00 Valid until: 20-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-and-treating-ibs-it-begins-with-one-simple-question/36607/ Presented at the 21st Annual Women's Health Annual Visit (WHAV 2025), this session reviews strategies for diagnosing and treating irritable bowel syndrome (IBS), with a focus on distinguishing IBS-C from IBS-D. Faculty explore the burden of disease, stigma, and the importance of a positive diagnostic strategy using Rome IV criteria, supported by history, physical examination, and selective testing. Treatment approaches include lifestyle changes, pharmacologic interventions, and brain-gut behavioral therapies. =

CME credits: 1.00 Valid until: 15-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/womens-sleep-health-addressing-gaps-in-osa-diagnosis-and-treatment-across-life-stages/36099/ This WHAV 2025 session addresses obstructive sleep apnea (OSA) in women, highlighting how phenotype and risk factors shift across life stages. Experts discuss how varying phenotypes contribute to delayed diagnosis and review screening tools, referral strategies, evidence linking OSA to cardiometabolic risks in menopause and pregnancy and available treatment options. The program underscores the importance of a precision medicine approach informed by phenotype, hormonal status, and patient goals at each stage of a woman's life.=

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Understanding-Endocrine-Resistance-in-HR-HER2-mBC/37323/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/PI3K-Pathway-inhibition-in-HR-HER2-mBC-Mechanistic-Insights/37329/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Comprehensive-Biomarker-Testing-in-mBC-Informs-Clinical-Decision-Making/37332/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Double-Take-Pivotal-Data-Evaluating-PI3K-Inhibitor-Endocrine-Therapy-Regimens-in-mBC/37333/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Triple-Threat-Key-Data-on-Simultaneous-Estrogen-CDK4-6-and-PI3K-Inhibition-in-mBC/37335/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Case-in-Point-Applying-PI3K-Combinations-in-Early-Recurrent-HR-HER2-mBC/37336/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/PI3K-Pathway-Inhibitors-Safety-and-Tolerability-Profiles/37338/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-PI3K-Inhibition-in-HR-HER2-Breast-Cancer/37339/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Understanding-Endocrine-Resistance-in-HR-HER2-mBC/37323/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/PI3K-Pathway-inhibition-in-HR-HER2-mBC-Mechanistic-Insights/37329/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Comprehensive-Biomarker-Testing-in-mBC-Informs-Clinical-Decision-Making/37332/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Double-Take-Pivotal-Data-Evaluating-PI3K-Inhibitor-Endocrine-Therapy-Regimens-in-mBC/37333/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Triple-Threat-Key-Data-on-Simultaneous-Estrogen-CDK4-6-and-PI3K-Inhibition-in-mBC/37335/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Case-in-Point-Applying-PI3K-Combinations-in-Early-Recurrent-HR-HER2-mBC/37336/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/PI3K-Pathway-Inhibitors-Safety-and-Tolerability-Profiles/37338/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-PI3K-Inhibition-in-HR-HER2-Breast-Cancer/37339/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 1.50 Valid until: 03-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/test-your-skills-and-learn-from-experts-on-il-13-inhibitors-in-moderate-to-severe-atopic-dermatitis/37624/ Watch an expert-led case discussion on the role of IL-13 in moderate to severe atopic dermatitis and the efficacy on its inhibition through biologic therapies to achieve control.=

CME credits: 0.50 Valid until: 02-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/crossing-boundaries-cetp-inhibitors-and-the-next-frontier-in-lipid-control/33025/ Cardiologists explore advances in lipid management, from statin intolerance to emerging lipid targets like ApoB and non-HDL cholesterol. The series emphasizes the pivotal role of combination therapy—including ezetimibe, PCSK9 inhibitors, and novel agents such as bempedoic acid and inclisiran—in achieving LDL-C goals. Special focus is given to cholesteryl ester transfer protein (CETP) inhibition as a breakthrough strategy, with trials showing potent LDL-C reduction, improved goal attainment, and promising effects on cognition and inflammation. Together, these discussions highlight how CETP inhibitors may redefine future cardiovascular therapy.=

CME credits: 0.50 Valid until: 02-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/new-insights-in-the-management-of-hcm-exploring-the-clinical-spectrum/33026/ This expert-led program delves into the evolving clinical management of obstructive hypertrophic cardiomyopathy (HCM), emphasizing real-world decision-making across diverse patient profiles. Through dynamic case studies—from young patients with unexplained syncope to older adults at a procedural crossroads—faculty explore how to tailor care using guideline-driven tools and therapeutic advances. Special attention is given to the role of the cardiac myosin inhibitor mavacamten, with discussion of long-term data, safety considerations, and its integration into personalized treatment plans.=

CME credits: 0.25 Valid until: 01-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-evidence-based-strategies-for-treating-patients-with-heart-failure-with-mildly-reduced-or-preserved-left-ventricular-ejection-fraction/29905/ Join Drs. Scott Solomon and John McMurray as they examine the new indication for finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in treating patients with heart failure with LVEF ≥40%. Drawing on data from the FINEARTS-HF trial, faculty discuss patient selection, dosing considerations based on renal function, and the additive benefits of combining finerenone with SGLT2 inhibitors. A clinical case illustrates typical comorbidities—atrial fibrillation, hypertension, and diabetes—and how finerenone may address multiple cardiovascular and metabolic risks. =

CME credits: 0.50 Valid until: 30-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommendations-in-first-line-treatment-of-her2-negative-upper-gi-cancers/37689/ This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.

CME credits: 0.50 Valid until: 30-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-in-anti-pd-1-strategies-for-her2-negative-upper-gi-cancers/37690/ This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.

CME credits: 0.50 Valid until: 30-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/distinguishing-first-line-treatment-adverse-event-profiles-in-her2-negative-upper-gi-cancers/37691/ This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.

CME credits: 0.50 Valid until: 30-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/quick-case-strategizing-treatment-selection-in-her2-pd-l1-gastric-cancer/37692/ This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.